Compare First Citizens BancShares Inc (FCNCA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Gilead Sciences, Inc. — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $25.04B), while Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 6.7× First Citizens BancShares Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| FCNCA | GILD | |
|---|---|---|
Market Cap | $25.04B | $168.35B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $155.80 |
52-Week Low | $1.64K | $110.56 |
Dividend Yield | 0.37% | 2.42% |
Enterprise Value | — | $191.42B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
